Inventors:
John M. Nuss - Danville CA
Stephen D. Harrison - Berkeley CA
David B. Ring - Palo Alto CA
Rustum S. Boyce - San Francisco CA
Sean P. Brown - Emeryville CA
Dane A. Goff - Redwood City CA
Kirk W. Johnson - Moraga CA
Keith B. Pfister - El Cerrito CA
Savithri Ramurthy - Walnut Creek CA
Paul A. Renhowe - Danville CA
Lynn Seely - Burlingame CA
Sharadha Subramanian - San Ramon CA
Allan S. Wagman - Oakland CA
Xiaohui A. Zhou - Berkeley CA
Assignee:
Chiron Corporation - Emeryville CA
International Classification:
C07D40104
US Classification:
514332, 546256, 546257, 546258, 546167, 546113, 546121, 546261, 5462681, 5462684, 5462697, 5462704, 5462711, 5462714, 5462727, 5462741, 5462764, 5462834, 5462821, 5462804, 5462801, 5462754, 544333, 544405, 544124, 544360, 544264, 544266, 514256, 514314, 514338, 5142315, 5142322, 514252
Abstract:
New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as in the treatment of diabetes, Alzheimers disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.